<SEC-DOCUMENT>0000950123-11-072963.txt : 20110804
<SEC-HEADER>0000950123-11-072963.hdr.sgml : 20110804
<ACCEPTANCE-DATETIME>20110804164029
ACCESSION NUMBER:		0000950123-11-072963
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110804
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110804
DATE AS OF CHANGE:		20110804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOGENEX PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000949858
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				954343413
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	033-80623
		FILM NUMBER:		111011007

	BUSINESS ADDRESS:	
		STREET 1:		1522 217TH PLACE S.E.
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021
		BUSINESS PHONE:		4254879500

	MAIL ADDRESS:	
		STREET 1:		1522 217TH PLACE S.E.
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SONUS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19950825
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c20786e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV style="font-size: 10pt">
<DIV
style="border-bottom: black 2pt solid; width: 100%; font-size: 1pt">&nbsp;</DIV>
<DIV
style="border-bottom: black 1pt solid; width: 100%; font-size: 1pt">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): August 4, 2011</B>



<P style="font-size: 24pt" align="center"><B>ONCOGENEX PHARMACEUTICALS,
INC.<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="text-align: center; font-size: 10pt" border="0" cellspacing="0"
cellpadding="0" width="100%">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>033-80623</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>95-4343413</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="text-align: center; font-size: 10pt" border="0" cellspacing="0"
cellpadding="0" width="100%">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>1522 217th Place
S.E.<BR>
Bothell, Washington<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>98021</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(425) 487-9500</B>
<TABLE style="text-align: center; font-size: 10pt" border="0" cellspacing="0"
cellpadding="0" width="30%">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>N/A<BR>
</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV
style="border-bottom: black 1pt solid; margin-top: 10pt; width: 100%; font-size: 1pt">&nbsp;</DIV>
<DIV
style="border-bottom: black 2pt solid; width: 100%; font-size: 1pt">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;2.02 Results of Operations and Financial Condition.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On August&nbsp;4, 2011, OncoGenex Pharmaceuticals, Inc. (the &#147;Company&#148;) issued a press release
announcing its financial results for the second quarter of 2011. A copy of the press release is
furnished as Exhibit&nbsp;99.1 to this Current Report on Form 8-K.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Exhibits</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><u>Exhibit No.</u></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><u>Description</u></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release of OncoGenex Pharmaceuticals, Inc. dated August&nbsp;4, 2011</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The information in Item&nbsp;2.02 of this Form 8-K and Exhibit&nbsp;99.1 attached hereto is furnished and
shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as
amended (the &#147;Exchange Act&#148;), nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth
by specific reference in such filing.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">ONCOGENEX PHARMACEUTICALS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: August 4, 2011&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Cameron Lawrence
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Cameron Lawrence&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Principal Accounting Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>EXHIBIT INDEX</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release of OncoGenex Pharmaceuticals, Inc. dated August&nbsp;4, 2011</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c20786exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><IMG src="c20786p2078601.jpg" alt="(LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011<BR>
and Provides Update on Development Activities</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">BOTHELL, WA and VANCOUVER, BC, August&nbsp;4, 2011 &#151; OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI)
today provided an update on current events and activities and announced its second quarter
financial results.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Second Quarter 2011 Highlights</B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Expected timing of results from the survival primary endpoint for the custirsen SYNERGY
Phase 3 clinical trial remains unchanged at Q4 2013.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During discussions regarding the SATURN Special Protocol Assessment, or
SPA, amendment, FDA stated that an application supported primarily by the results
of SYNERGY alone would be acceptable for submission.</TD>
</TR>

<TR style="font-size: 8pt">



</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We have revised the custirsen SATURN Phase 3 trial protocol to expand the eligible
patient population, and to align with the recently approved chemotherapy, cabazitaxel.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We are awaiting final, written FDA agreement on the SPA amendment that
will allow patients to receive either docetaxel re-treatment or cabazitaxel as
second-line chemotherapy.</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Recruitment efforts are ongoing to enroll more patients in the SATURN
study, which has had few patients accrued due to restrictive enrollment criteria
regarding docetaxel retreatment and stable pain criteria. Expected timing of
results for the pain palliation primary endpoint is now projected to be Q4 2013
rather than Q2 2013.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The initiation of the Phase 3 clinical trial evaluating custirsen in patients with
non-small cell lung cancer (NSCLC)&nbsp;has been delayed as we determine the optimal
chemotherapeutic combination based on safety considerations and the current and evolving standard of care.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We believe NSCLC is a promising indication and remain committed to the
advancement of custirsen in NSCLC.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>OGX-427</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Enrollment continues for both the investigator-sponsored, randomized
Phase 2 clinical trial evaluating OGX-427 in patients with castrate-resistant
prostate cancer, and the investigator-sponsored Phase 1 trial evaluating OGX-427 in
patients with superficial bladder cancer. We expect results from both trials in
2012, unchanged from previous guidance.</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We expect to initiate the randomized Phase 2 clinical trial of OGX-427
in approximately 180 patients with metastatic bladder cancer in the second half of
2011.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Financial Results</B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Revenue for the second quarter increased to $1.9&nbsp;million compared with $1.7&nbsp;million in
2010. Revenue for the six months ended June&nbsp;30, 2011 decreased to $3.1&nbsp;million from $6.4
million in 2010. Revenue is earned through reimbursements received under the Teva
collaboration, as well as recognition of upfront payments we received from Teva.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Revenue increased for the second quarter of 2011 due to increased
efforts associated with the custirsen Phase 3 clinical trials.</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Revenue decreased during the six months ended June&nbsp;30, 2011 due to
custirsen manufacturing activities now being paid directly by Teva.</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As of June&nbsp;30, 2011, $19.9&nbsp;million of the $30.0&nbsp;million upfront payment
received from Teva in December&nbsp;2009 was included in our Balance Sheet as Deferred
Collaboration Revenue, which we are recognizing as we perform our deliverables
under the agreement. We currently expect this performance period to end in the
fourth quarter of 2013.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Total operating expenses for the second quarter increased to $6.9&nbsp;million from $4.6
million in the second quarter of 2010. Total operating expenses for the six months ended
June&nbsp;30, 2011 also increased to $13.3&nbsp;million from $12.3&nbsp;million during the same period in
2010.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The increase in operating expenses was primarily due to higher
manufacturing and clinical trial costs for OGX-427, and higher employee expenses,
offset by lower custirsen manufacturing costs that are now being paid directly by
Teva.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Net loss for the second quarter of 2011 increased to $6.5&nbsp;million, or $0.67 per diluted
common share, compared to net income of $0.2&nbsp;million, or $0.02 per diluted common share, in
the second quarter of 2010. Net loss for the six months ended June&nbsp;30, 2011 increased to
$9.6&nbsp;million, or $0.99 per diluted common share, compared to net loss of $2.9&nbsp;million, or
$0.45 per diluted common share, in the same period of 2010.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>An income tax recovery of $3.0&nbsp;million was recorded in the second
quarter of 2010, in relation to the Collaboration Agreement with Teva.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We had $75.4&nbsp;million in cash, cash equivalents and short-term investments as of June&nbsp;30,
2011, compared to $85.1&nbsp;million as of December&nbsp;31, 2010. As at August&nbsp;1, 2011, we had
9,725,489 shares outstanding.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Conference Call Details</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">OncoGenex will host a conference call at 4:30 p.m. Eastern Time today, Thursday, August&nbsp;4, 2011, to
provide a business update and discuss the second quarter financial results. A live event will be
available through the Events and Presentations Web page found in the Investor Relations section of
the OncoGenex Web site at <U>www.oncogenex.com</U>. Alternatively, you may access the live conference
call by dialing (877)&nbsp;606-1416 (U.S. &#038; Canada) or (707)&nbsp;287-9313 (International). A webcast replay
will be available approximately two hours after the call and will be archived on <U>www.oncogenex.com</U>
for 90&nbsp;days.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>About OncoGenex Pharmaceuticals</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">OncoGenex is a biopharmaceutical company committed to the development and commercialization of new
cancer therapies that address treatment resistance in cancer patients. OncoGenex has a diverse
oncology pipeline, with each product candidate having a distinct mechanism of action and
representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical
Industries Ltd. (NASDAQ: TEVA) have entered a global collaboration and license agreement to develop
and commercialize OncoGenex&#146; lead drug candidate, custirsen. Custirsen is currently in Phase 3
clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The
companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced,
unrespectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development; CSP-9222 and
OGX-225 are currently in pre-clinical development.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>OncoGenex&#146; Forward Looking Statements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">This press release contains forward-looking statements within the meaning of the &#147;safe harbor&#148;
provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to,
statements concerning our anticipated product development activities, such as expected clinical
trial initiation and completion dates, patient enrollment targets, proposed amendments to our
ongoing clinical trial design and the timing and possibility for approval by the FDA thereof, the
timing and costs of our product development activities and the potential benefits of our product
candidates. All statements other than statements of historical fact are statements that could be
deemed forward-looking statements. These statements are based on management&#146;s current expectations
and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those described in the forward-looking statements. Such
forward-looking statements are subject to risks and uncertainties, including, among others, the
risk of delays in our expected clinical trials and the uncertainties
regarding patient enrollment rates, the risk that the FDA does not approve our proposed amendment
to the Saturn trial design in a timely fashion or at all, the risk that our product candidates do
not obtain the requisite regulatory approvals to commercialize, the risk that new developments in
the rapidly evolving prostate cancer therapy landscape require additional changes in our clinical
trial design or limit the potential benefits of our product and the other factors described in our
risk factors set forth in our filings with the Securities and Exchange Commission from time to
time, including the Company&#146;s Quarterly Report on Form 10-Q for
second quarter ended June&nbsp;30, 2011.
The Company undertakes no obligation to update the forward-looking statements contained herein or
to reflect events or circumstances occurring after the date hereof, other than as may be required
by applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">SOURCE OncoGenex Pharmaceuticals, Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>OncoGenex Contact:</B><BR>
Jaime Welch<BR>
(604)&nbsp;630-5403<BR>
jwelch@oncogenex.com

</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt">Condensed Consolidated Statements of Operations<BR>
(in thousands)
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three months</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six months</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Ended June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Ended June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">(unaudited)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">(unaudited)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">(unaudited)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">(unaudited)</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Collaboration revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,887</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,701</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,086</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">6,401</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,409</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,079</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,262</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,459</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,471</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,475</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,042</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,825</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,880</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,554</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,304</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,284</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loss from operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,993</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,853</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,218</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,883</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other income (expense)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,537</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">643</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(7</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loss for the period before taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,530</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,846</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,575</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,890</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Income tax expense (recovery)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,000</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">6,530</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(154</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">9,575</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,890</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Basic and diluted loss per common
share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0.67</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(0.02</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0.99</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0.45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted average number of common
shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Basic</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,718,251</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,400,081</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,715,846</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,366,861</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,718,251</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,529,482</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,715,846</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,366,861</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt">Condensed Consolidated Balance Sheets<BR>
(in thousands)
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">(unaudited)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Assets:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash, cash equivalents and short term
investments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">75,412</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">85,107</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Amounts receivable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,498</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,224</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Prepaid and other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,899</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,987</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Property, equipment and other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">716</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">600</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">79,525</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">89,918</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Liabilities and stockholders&#146; equity:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accounts payable and accrued expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,643</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">893</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Current deferred collaboration revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Warrant liability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,828</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,269</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,384</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,314</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Long term liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,472</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18,317</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Stockholders&#146; equity (deficiency)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35,198</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44,125</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total liabilities and stockholders&#146; equity (deficiency)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">79,525</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">89,918</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c20786p2078601.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c20786p2078601.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`$(`T0,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`"@`Z>U`;!]*`$X'M^E`"T`%`!0`4`%`"9'M_A0&P
MOZ4`(".U&VFP"T`%`!0`<#V_2@`H`.GM^E`!0`4`%`!0`4`%`!0`4`%`!0!S
M/C+Q7HG@3PKXB\9^)+M;#0/"VC:AKNK71QNBL=-MI+F<1(2/-N'6/9'$#NDD
MD1%RS`5G5JPH4YU:CY84XN3]$CJP."Q&8XS"X#!TW4Q.+JPHTXK^:<E%7[)7
MO)[12;>B9^3WPT\4^*/VN'\:?'3XVZUXVT3]G_P]KS^&OAO\$?`%_KMC>^-]
M:C>*>&RU&#PO)!J/C#4?*GM;<QQS!9;N>X"&TM;&7?\`-X:I4S+VN,Q4IPP4
M)<E*A3<DZDKJRM'63U2WU=]8I,_9,WP&%X)>`X>R&CAJ_$E>C]8QV9XJ-)QP
M=*SBY1E6O##134I/F7NPC'F56I.,CZ@^"7Q7\!^%_B6/@K/X;^+7P8U;6=*>
M_P#!GP]^+-X-9T37K6R5<7G@+Q%)K^LO:77E0W9N=(.I/&S1N8X8YXI`_HX7
M$4:6(^J.%7"R:]RE5?-&26SIRO)KK>-[-JVC3/D,^RG'XS*5GL<1@,[I4*G+
MB<;@8>RK4I3;O#%T53I1FDW'DJ^S4E%QO*5.47'[F'0?_JKUSX#^NPM`!0`4
M`(>A^E`'P=\2/C7\1_BC\;+O]FG]GC5;+PO<^%;)=2^,OQ@NM/AUE?!5I.$2
M/P]X7TVXS;77BF0S(GF7.Y8Y=Z!5^R7$D7D5\76KXMX#!-0=-7K5FK^S7:*V
MYNFO7M9M?H.5Y!EN49##BGB.C+$0Q<N3+<OC)T_K,D[NK6DGS1HI)OW=XVD^
M;GA&7CGQV\)?%O\`9*NOA]\9_!7QX^*WQ$T*;QQX?\)_$3P3\3O$+^)[#7;/
MQ'=F$W>D62PP6^F3LT<L0BM88F@>:WD@=4CDBEY,72Q.6NCBJ.+K58>TC&I"
MK)S34M;I;+:VBNFU9I73]WA_&Y)QC2S+(L=P]@,LKQPM6O@\5@:*H3I2I65J
MLM922YDVY-QDE)3BVXR7ZI(>`0"`P4@,,$9&<$=CS7T*VTT_0_(FK-KMV'TQ
M!0`4`<+\3O%%_P"!_AQX^\9Z5IR:OJ7A'P9XG\2Z?I,CO''J5[H>BWFI6UC)
M)$"Z1S36R1L4&[#G'-8XBHZ-"M5C'FE3A*27G%-I?,]#*<'3Q^:9=@*M7V%+
M&8FA0G4M?DC5J1A*5GI[JE?Y#OACXK?QW\-_`'C:58(Y?%W@OPQXFF2U#K;)
M-KNBV6IS);K([,L"RW+!`S,0H&23S1AZGM:%&KM[2$9?^!13_4,UP:R[-,QR
M]-M8+$UZ";WM2JR@F[65[1UMU/@?]N_]MJ+X(Z;=?"[X9WL$_P`6=7L,ZGJL
M9CGA^'NF7L0,5U)'DK)XHNH)-]G;N"($9;N92&@CN/&SC-E@E]6P]I8F>[Z4
MTUO_`(FM4NF[Z)_I'ASX?2XAJ?VQFT'2R3"-N,7H\74A=<JV_<J2M-_;=Z<=
MIN/W1\'$\0Q_"7X9+XMN;R]\4CP#X1/B*[U"1Y=0N=:;0;!M2GOI9/FDO'NS
M*TK-\Q<L3R:]C"\ZPV']HVZGLX<S>_-RJ]_.Y^>9Y]5_MK-OJ4(T\']<Q/L(
MP248TO;3Y%%*R45&UDE9+8](K<\H*`"@`H`*`"@`H`*`"@#\[_\`@I[XIO?#
MG[+]WIUD\D0\8^./"WAF]:-V0_8$74O$<\;%2,I+)X?AB93D%9&!'->%Q%5=
M/+I1CI[6<8:=K.7_`+:?J/A!@:>+XQI5*B36`PM;$137VN:G15O-*LVGTM<]
MM_8R\)V'A7]E[X(V-M!`&N_!>G>*)95BC#G4/%J3:_=S%PH/G8U9X"_WBB;2
M2.*[,JI1IY=@TE9>S4_G/WG^9\[QYC*F+XPX@J3;7)BJF'2N_AP[5%:7V;I\
MUMKNY\V?\%-8F\,^"/@O\7],D6U\2?#7XQZ)+I5ZJ@3K%J%E>ZI/"9``QMVN
M?#=F7CSM<`@@@FN#B#]U2PN*CI.A7C9^33E;TO!:'U/A-;%X_/<CJQ=3#9GE
ME5SC?2\)1I)V_FY<1-1ENGL?I3IU]%J6GV&HV^1;ZA9VM]`#U$-W`EQ'G'?9
M(M>_%IQC);22:^>I^5U:<J-6I2E\5*<H/UBW%_BB[3,Q.?2C\`%H`P?%.N1>
M&/#'B/Q)/&98/#V@ZOKDT2\-)%I.GW%_)&ONR6Y`^M15G[.G4J6NJ<92M_A3
M?Z'3@\.\9B\+A(M1EBJU*BF]DZDXP3?HY7/QW_X)[?'+X7>"O!?QJ^('Q9^(
M'AG0_&7CWXE-JU[;7MZMSXMUBV73UOQ/9^'K%9]5U"S&J:UJ@0VUI*BLT@R,
M<?+Y%C*%*EBZ^(K0A5J5>9K>;7^%7DU=O9:'[AXH<.YKB\=P_EF39;7K8#`8
M%4X24>7#TY-J/*ZT^6E&?LZ<+J4U*22T9]-_$#Q?:?&-_#GQ"^*FGWGP?_94
M^%FOZ9X[6_\`B'!+H7BOXL>,=++_`/"+1Q>%'5[_`$GP;9W4[7:07,/V[5IE
M@2&V6%6<^E6J+$.%:NGAL!AY*:=1<LJLU\*Y-U!=K7ET7;XS+L%4R18G+LIJ
M1SCBO,Z,\,X81JK0P&&DDZ\G7_ASKR44G*,E"A9\TN;1_?6DZI8:WI>G:UI-
MU'?:5K%A9ZIIE]`28;S3]0MX[NRNX2P!,4MM-%(N0#AQD5Z\)1E&,X-.,DI)
MKJFKI_<?GM:C5PU:KAZT'2K4)RIU(2T<)PDXSBUT<9)IFC_G%49A^E`!0!FZ
MOIL&LZ5J6CW0/V75=/O=-N0`"?L]_;2VLV`>#^[E;@\5,HJ490>BDFOO5C6A
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MX1]=5'&_B%]8A_JYPK+ZAD."7L74H_NWB%%<MJ;C;DH6T35I5%U5-\K_`%#K
MZ$_(0H`*`"@`H`*`"@`H`*`"@#\^/^"FO@V_\4_LOZGJ&G123-X'\7>'/%]Y
M%$NYO[-B74-`OIB/^>=O%K_VASV2W8]J\/B&BZF73<4[T9QG9=M8O[N:Y^G>
M$>84L!QC0A5:A''X>MADV[)2;A67SE[%Q2ZMI'M'[&7BBQ\6?LO?!34+&2-A
MI_@C2_#-VB.K&"_\)H_AV\BE"D[)/-TTR;3@[95..:Z\IFIY=@W&UHTU'YP]
MU_D?/\>X.I@N,,_I58M.IBZE>+:M>.)?MXVOT2GRW6ETSYE_X*=7(\0>`O@W
M\(M-C%UXF^)'QAT2/2+))%69X["SO=(FD\LG(B^V>)[",R$!5WY)P#7!Q![]
M'"8:*O.O7CRKT36W:\T?5^$L?JF8YYG=1^SPF5Y;5]K*VBYYQJK7:_+AYNV[
MZ'DVB?$OQW#^V'\=?A/I?C/7EUC6(O`GP>^&ELL\D]KX-\,QMI>I^+?$FD:7
MN-M:WND>$K'7+Y+GR78WUW;M,61WKGAB*L<TQF%C4ESR]G1I+?DAHY32_NP4
MG?\`F:OU/7Q.38"7`^09Y4P-+V--XO,,=)^Z\17_`'D*%"4])25:O.E!PYE>
ME&2BU:*/2/V?O&,G@']L;]I3X2Z'?^))/A1X1\%VOB0Z9KWB77_%;V/B+1M/
M\-3:UK4%_P"([V]NX)[^75=26:%)Q$Y@B*H!&BIM@JOL<TQV%AS?5Z4.:TI2
MG:45%N5Y-N[;EIMY:67F<29<LPX'X5SNO"BLWQV)=#FI4*.'3I3GB(TZ?+1C
M"#48PI--QYKN3;O*3EXO\,/AW\3?VY/AQ\:/C/>>/];\/_$"_P#&]OH7P9AF
M\3>(])\)>`=%T"ZT_6;ZPMM/\.72*D]Y8:A_9SWTEI=2J\#7(5I+B1JYL-1Q
M&;T,5B76E2K.IRT??DH4XQ:;5HZ.Z?+JGMS;NY[N<9EE'A[FF0Y'#+:6+RZE
MA95LR:H49XC%U:T94X2<ZRNE&=/VO+&<+J7L[J$8Q/:_BAXE^,\WC_\`9?\`
MV-+KXDZE8:YXH\(1:W\9OB9X7NIM/\1^(K#1++5GU#3=$U66!+C3VN[;P]J?
MF7P1)YWN8&=4`FBFZL14Q2KY?E;KN,ZD+UJL&U*2BI72>C5U%ZVNVU?JG\_E
M&"R197Q9QS#+(5,/@L0Z>6X&M%2HTI59TXPG5IJ3C)1G7IVA=J$8RY7=QG'"
M^)9\5?L[_&_P_P#`SPIXG\6^)OA1^TG\/?&7A?3O"?C'Q!?>*+KPCXZN]+U'
M1M/O?#^N:W<3W]M87&I7FD"X@GN9(MNHW;X+0P>5%?GP.*IX.E.<\/CZ<X*$
MY.7)-QY4XN6MFVKJ_5[V5NK*(X3B;(<3Q%C,+0PF;<+8S#5ZF(P]&-%8C"PJ
M0JSC5I4U&#E&E&JHVC?FA37NJ4^;$_X),-H5QX'^*.EWFG:2WBKPQXUL;Q9Y
M].M/[=T_3M9T2*S6,7SP_:8K8W^B:@GE"0*KQR<`L<Y<,\GL<3%Q7M*52^L5
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M>(5M?!5K+I_A[4/$]E<6U[I'AVVLXX;RZ^PW-O)<F7RVD`C&.2.*C.>"P52H
MZ6'AA85:K4N1RM3TBY)IJ*5F[.[^YGT53(ZN!P_$O$N#P<<;F^(SW$8++Z<J
M2Q"I.6*:E5A1G&=.I5E)RA'VD&H\J:NG)/Q+5?'WQ1\/?L3_`!RUOPIXI\=Z
M7\.=1^.HT;X+Z_JFIZH/$5S\+=6U.>WN[2QU?493J@T*?;#&DKRAV:6\0/\`
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M247)Q[2;EH^B3]3Y[A[A;`5LYXQQ-6BL7@>%'C)4,/).4*\Z52NJ,:B6LJ:C
M0?-&]Y2E&]XJ47F_LVW^G:+^U+\=[#X6^(_$6K?LY>$O`>G0^)=9USQ3KWBS
MPU:?%'3KBSFU&;1O$'B&_O7GN%L%UQKQK>X:$-%(>(EM11@6J>88N.'E)X&E
M32E*4Y3BJJLVXRDWTYK^CZ<I7$].>(X1X?J9IAJ-+B?&8N7L:5&A2P]9X*2J
M1C&I1HPIJ-Y>PY>:/,[Q^VZI\V?LUS_#7XG_`+;NM_%'Q=H.I:+H?CW4/&/C
M+]G*TUA8X_#?B+6])U5-(U_7X8K@X/B!_P"S;G4H8(U"K=&=BSS6MLS^=@'0
MK9O/$582IPJN4L*I*T)--IR2?VM&U_>OU2/K>*EF>4>'V%R?`8FG7Q&`AA\/
MG4J5W7HTITU.G2DUM17/"DY-ZTW&R49U+?N4,=O\YKZ\_GW;R#(Z4;>0>6UA
M:`"@`H`*`"@`H`*`"@`H`S-9T;2_$.D:GH.MV-OJ6C:UI]YI6JZ;=IYEK?:=
MJ$#VMY:3ID;HI;>61&&0<,<$&IG",XN$DG"2::>S35FC6A7JX6M1Q.'J.E7P
M\XU*<XZ.$X-2C)>::31^>/@7X#?M&?LGZIXGTK]G\^#_`(M?!SQ#JDVM:?\`
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ML34=N2<(U)U*48M2U3<X.2E%<LJ2LWS:<[KOP`^,/A3]HGXJ?%3X0)X#GT_X
MX^$-'\/:SJ_C"]O4E^'FI60L;35=7M_#MKI\J^*X[FPL8KBWLVN;9'O!LNG2
MW!:12P6(IXW$8C#*G;%PC&3F_@:Y4WRI>]=*]MFWKIOMA^),EQG#.3Y/G+Q4
M:G#^(J5:5/#QC_M<).K.$'5<E[&TJG)*=G*--7I\TG:-#X(_`SXY_LHOXV\#
M_#;2O"'Q5^&7BC5SX@\)WOB;QA<^#O$'A#69["WL;I/$MM!X<OX-4T=Q:6K%
MM*59R8681*9BJ1@\'BLM=6CAXQKX>H^:#E/DE"5K>\K.\?.";ZFW$/$60\9+
M`9CFE6OE&:X2FJ.(C0PZKT<124W)>Q;JP<*JYI/]\U!*2C=J*;=X^_9-^(U]
MXA\`_'KPIXST&_\`VEO!WB*YU[7;O6TU33/`/BO1K^%;1_A_80VINKSP_P"&
M]+TKS]/L)=L\TRWU]/>,9[OS+=U\NK.K1QE.I'Z]2DVV[JG*+T]FEJU&,=$[
M7=VVTVK1EG&.74<'F/#F*P56EPMCJ,:5.-/V<\71JP?-];E)\L:E6K4_>3CI
M"#C3C33C!J>]X>^`OQ/^)W[0/A?]H'X]VOA+PS#\-M)DTWX;?#7PGJUWXE^R
MZE.UP\_B+Q+K]S864,UPD]S+-!;VD+`-'9L[H;4K/<,'7KXVGC,7&%/ZNK4Z
M<&Y6;O[TG:V[;279;6=\,1Q'E>4<.8OAOAV>(Q+S2ISXW&5Z<:-X)17L:-)2
ME)1<8J,I3Y79U-)<Z<.5\1?LI?$_X4?''5_CS^RSK7A&V?QB;D^/_A7XYEU+
M3O#>LM>W2WU_-I&HZ1;3M9R37RFZB26)/LMQ-,T<K03O;5E/+:^%QDL9ETX1
M]K_$HSNHN^K::\]5M9WU:T.[#\8Y5G'#U#ASBZAB)K`)+!X_"J$J]+E7+"-2
M-1J\5%\LFN;VD4DXJ?[P^>_VNO'WQ)\9_#_XC^%_B19:!J$W@CPTVJZM\/\`
MX/:EJFK>%O`^L7<EK;Z-XG^,?Q(UVVTV&;5K,WGFZ1X(TFSFFGN&AOKMGBC@
M\KCS.IB*E"O3KQB_9QNZ=%MP@VTE.M4:CJK^[2BG=VD^A]%P5@,JP&:99B\K
MJ5Z$<96<88O,:=.&(Q%*$93J4,OP=)U&H5%!>VQU645&'-2A%/GYN@LOV,OB
M+JS_``"^.-VGP[^+NO>&OA]X1T?6OA)XOTV3P=X6?PUIWAN&'PM::9J$$6IG
M4/$.E_:GFN)M<CE@NKN-7"P011VZ5'*:S>"QC]GB)TJ4(NE*/)'E44HI-7O)
M7NW/1R2V6BRJ\=Y9AX\3<.4OK>387&8[$5:>88>I]9K>VE7;K2G&7)R4:G+R
MPC0M.--M:S;J/V#XZ_LX?'3]I+X9ZWHWBC4/!?PZGTO^QV^%OPN\-:QJ5UX3
MTVYM+^V^W:OX^\06^D0?VOJ::&;RRL+&PTX6%B7:4>?+.)+;JQN`Q6/PTJ=2
M4*'+R^RI0;Y%KJZDDK-\MU%)<JZ:O3PN&^*\CX2SBABL'2Q&9*HJOUW&UZ<%
M7GS0ERPPM*51\E-U>6I4G4FJM163LHVEZ?\`$W]E6S\4_LC0_LW>'-1M[2]\
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ML?P^+/@3X$\-?!Y3HGQ`^`UK8W7POO;6Y_LR_O$TZW@74M*.IQ.AMM2U&6TA
MOXKIG4#4+>-G=$GE>NK'Y7[3!T:>%]RO@TO8M.S=MTWI9R:4KW^+UN>!PGQN
M\#Q%F&+SM*OEG$,I+'P:4H1YY2Y)J%FN2DI.GR*+7L791ER1B?"_A7_@IA^T
M1X%$?P_^(GPHT_Q;XWTR>/26-];:YX5\5W-TBQP1PZIHEI83I=ZE))AB]K;6
MPE,H*Q_,"WCTL_Q]"U"O@_:5HV6THROTNDMWZ*Y^D8SPEX4S!/-,JSYX'+:L
M7545*G6I15VY.$Y-.,(KO.:5GK;1?L/\"_%'Q,\:?#G1O%7Q8\(Z?X#\5:Y+
M=WZ>$K&2[DET719)L:/!JIO?WJ:P]J/.GC(3R_/5&1'1T7ZG"5*]6C&IB*2H
M5):\JWBM+)WUN]7Z:.S/PC/\'E>`S.O@\GQDL?A,-:/MY**52HK\[ARZ.">B
M:NFTVG*-F_8JZCQ@H`*`"@`H`*`"@`H`*`"@!,"BR[```'3B@`P/2BP;;:";
M11^@6L+@>E&P!@>E`;!M%';R`I:DEZ^GWL>FS0VVI/9W2:?/<(9+>"^:!UM)
MIXQ]^%+@QLR]PI'>IES<K4-)6:3:T3MH_O+I.G&K2=6+E2C*+FHNS<+KF2?1
MM72?1GY96?@OQW\1/@SX5_95M/A)X\\&ZOJOBK2M3_:4^(GBW3[6T\.W_P#9
MWB&#Q)XSUW3/%:73R>/->\4ZK96K64MHC;;:9!,]O%;A8_`]E5KX:GEZP]2G
M*4D\34FDHZ2YI24MYRFTG%KHNBV_698[`97G>+XMEG&%QE&A0J0R;"4)2=6'
MM*+HT:4J#2CAJ6&IRG&JI.RDVTI2=G^AOBCXJ_#+X<W^F^'/%/BO2?#E[/I\
M%U965W]I5(-)^U+I5O?74\,#PZ=IWVL"`7%W)!%N1AO^1L?0J-DDE91T7EY'
MY'.=Y2<Y>])N3]6W=^K9W>H:IIVE06US?7*6\%Y?:?IMM)MDE6:]U:ZALM/@
M7R4?'G74\2!SA!O!9E4$@V#0TMH].E`&>-2L/[4DT59Q_:<5A%JDEILE#+87
M%Q/:0W'F;/+PUQ;3IM#EODR5`()`/%O%'P5'BOX]?#/XR:CK2-I_PP\*>+-*
MTCPN]AYA?Q'XH>VMVU\7SS;81#I2SPA!`7W^6PD"[@>.IA%/%T,3*6E",E&/
M]Z5_>\M/T/H,)GKP7#^:9)2HM5,TKT9U*RE9>QH^\J?*E=MS2=^:W+*2:O8]
MECU?2Y-7N-`CO;9M9M-/M-5N=-60&Z@TV^N+NUL[V6+^&":YL+R-&_B:VD'\
M-=GX'SVFW4L/IFG/>1:C)863ZA`ABAOGM8&O88VZQQW31F5$/=58"IY8WYN5
M<RV=E=?,U56K&FZ4:DXTF[N"DU%ONXWM?Y%O:!]156,R);B`W#V@GA-W%#%<
M2VJRH;B.WG>:.">2$-O2&22WN$1RH5F@D`)*-@`HZKK6E:%%:SZO?VNG07NI
MZ9HUI+=2"))]5UF]AT[2K",G[UQ=7UQ!!&O\3RJ.]`OP,>T\<^%+[5=,T.TU
MJVGU?6+?7KO3M.6.Y6ZN+7PQJ2Z1KET8W@!@M[74W6V,LOEK(YQ$9*!W70ZT
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`AZ4`?$O[1?A[QMJ/C'Q`OANP^
M*<]KXJ^#<7A&S7P!HWAS4="UK7!XB\0R_P!@^-+[78R=$TF2VU2WCEN89;,B
MSU+4"LZRQQE*C9+M9W_X8B47?2^JMI^INVG@;Q[9WWB'Q(J>,8-?D^-?PXTO
M3[.T\3:L?#UI\*;"_P#AE<>((M$T*3418V_AU#8^)!+*;9;J6'[8C%DG*,:+
M;L_O"SZ76J]+'E\'@_XLZ!X91K]/B?<V7B'2/"&I_$FP?QC>RZ[J5Q;_`!;N
MU\0:1X7N[S7(GT;7;SP+=6UN+/2+FP-U96\5M`?MC1EWITZ/024E;T5U\]?P
M+?A72_B'XT\(^$TTZY^)$WA+5+GPCIUW.WB^Z;6(=$L/VA/%Z>(K2_U^PU9K
MB2]M_`4.G6M]=6]U)))9QK$D\A4-2T5UVO\`D"NTK;:?==W,CQC:>//")\%P
MZS-\3PFEZUX;\/\`@B_M/&<XBTA'_:,.D2'QU&VNQ7.OQZM\-Y_#EG:3WUOJ
M;W5M%=P+MNY)6=Z=-`=XVWTV?S_R/:_BGX&\6:A\3;SQQX=M?%:7VA>'OA+!
MX>NM"UFZT^PO)X/BGJ$WC&RO]-@O(K?6T3PA>W0GAOXIHQ;7DGE`3$,B35DO
M7\AM.]TNUOOU7W'A&O0_$_0=-\4W'B*+XKV<=WXI\%:1XXE@\0WT+>,M?U;X
MXZ6EH/A-*FKJ+'3+CX;7$UA)#IHTR-H)[.Q=3J$4C(]-E\NG0GWHWU:[_-]/
MD=):>&OC!)KOPO8R?%30_#D-P[^$VGAU7Q%K?ANQ7XHZS?+IWQ&5?&UI;(]S
M\+Y/#NG23^(4UHQ6ZWD2?\3*(K<+2SZ?AT&D_=W2_P"#UU/1/B]X/\4'Q[XU
M\2>&-"\:7$^O?#3X>:5<:IX5U6YM9;SP[X9^).HW_P`1/#&D_P#$UABTSQA>
M>$=81M.E2&&>8&]2TNHK@'<*UK=F_P`AR3OIY?GJBR=#\9M\&/"IGT#Q?J,N
MA?%WPQXKTSPYJ\O]J>.[+X;Z+\6;;6-&L]4%[J$LU_K5CX/BMW:WGNYKL1P+
M#*TEU&X8TN_3]`L^5*VS3UWM>_Y'F&N>`?B_-!KGB2ST[QB?%J^#/%6AG4/[
M8OY+^Y\.S?M%ZCK=UHFGVUOKUF)M6G^%Q<Z<8YK:Y6&6W@M[F";9L+I>G_`)
MY9=%KK]SE=_A_2/IKX+2ZUI?A30/#>MP>-KR?[!K>LVVK^*=$GTIM.TN7Q+>
MPZ-X5OSJ7B'5=2&IV>ERVJVZW]S<7,EC;Q274B7&^)4]]-BXJT4MK'M5(H*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@!,>^*`#'\L4`96M:%HOB32[O1/$.DZ
M=KFC7Z+'?:5JUE;ZAI]W&DB3(ES9W4;Q3!98XY%W*<,BL,%00>F@6Z%FPTZP
MTFQM-,TNRM--TVPMXK2PT^PMH;.RLK2!!'#;6EK;HD=O;QQJJK'&JJH4`#`H
M`R]0\)>%]6UC2/$.J^'-#U+7O#_FG0M:O]*L;O5=&,^/..F7\\#36)?`SY+I
MD\T`=!CW(]/:@"G>Z=8:E%'!J-E:7T,-U:WL4-[;0W445Y8W$=U8W<<<R,J7
M-O=11312@!HY(U=2&4$`6+F/\]/SH`-N.F1SF@`VT`&/<T`&*`%H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`/_
!V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
